In a study, Medical Research Council scientists demonstrated that a test that uses flow cytometry and looks for the CD63 protein in mast cells had 98 percent specificity.
Participants in the financing round included CS Investors, Pivotal Paramount Investment, and Stanford University.
The team developed their method to facilitate tumor cell movement through the blood-brain barrier for cancer biomarker detection. The method could eventually lead to the detection of brain cancer using a blood test.
Their machine learning technology coupled with digital holography produced an 84 percent success rate in predicting canine responses to chemotherapy.
Hologic's device will potentially increase sensitivity for cervical disease detection in US laboratories that employ the firm's automated imaging system.
In developing the new tools, Google trained artificial intelligence algorithms to aid pathologists in making breast and prostate cancer diagnoses.
Providers are looking to innovation in products and pricing to convince pathologists unsure of the value in switching to digital solutions.
The firm's algorithm rapidly identifies skin irregularities by comparing the image to data from its cloud-based database, acting as a diagnostic aid for pathologists.
The firm recently announced a $3.15 million grant from the NIH, and it supported work that resulted in the first-ever digital primary diagnosis of a suspected cancer case.
The device uses neutrophil movement and its correlation with infection to detect sepsis. A commercial version could be several years away, however.
Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.
The five-year award will go toward developing a tool that will be based on digitized hematoxylin and eosin (H&E)-stained pathology images alone.
The assay is for diagnosing lupus and is the second immunofluorescence assay cleared by the FDA for the Helios platform.
The device being developed will interpret the scattered patterns of light that has passed through the body to enable cellular-level imaging and will compete with biopsies and blood tests.
The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.
BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.
A meta-analysis concluded that combining a biomarker blood test with ultrasound increased the detection of early-stage liver cancer by as much as 40 percent.
The approval follows a validation study that included 3,300 cases and 6,600 FFPE glass slides at four sites in India.
Inspirata's CEO said that with the Omnyx acquisition, his firm has achieved an objective of having an end-to-end integrated pathology solution.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.